RCS - Futura Medical PLC - Pre-launch of MED3000 ahead of H1 2023 launch

Futura MedicalAnnouncement

26/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230126:nRSZ8764Na&default-theme=true

RNS Number : 8764N  Futura Medical PLC  26 January 2023

 

 26 January 2023

 Futura Medical plc

("Futura" or the "Company")

 

Pre-launch of MED3000 Eroxon™ ahead of H1 2023 launch

 

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, announces
that its partner, Cooper Consumer Health ("Cooper") has initiated pre-launch
activities ahead of the launch of MED3000 (Eroxon™), Futura's breakthrough,
topical gel formulation for the treatment of erectile dysfunction ("ED").

 

In May 2022, Futura announced an exclusive licensing agreement with Cooper, a
leading International independent self-care organisation for the rights to
commercialise MED3000 throughout the EEA, the United Kingdom and Switzerland.

 

Futura is pleased to confirm that Cooper is on track to launch Eroxon™ in
the first half of 2023, as previously guided, and has already commenced
pre-launch activities and expects the first product supplies to be available
in the coming months.

 

James Barder, Chief Executive Officer of Futura Medical said: "As part of our
close strategic partnership with Cooper, we are pleased to note that as
planned, Eroxon will soon be made available to men suffering from ED,
especially those with mild and moderate ED, to improve their erectile
performance in a fast, safe, effective and accessible way. We look forward to
updating the market further in due course."

 

MED3000 is the first pan-European topical treatment for ED available without
the need of a doctor's prescription and available over the counter ("OTC").
Subject to US Food and Drug Administration ("FDA") granting Marketing
Authorisation, MED3000 has the potential to become the first major ED
treatment available OTC throughout the USA.

 

Futura has established a network of licensing and distribution partners with
strength in brand building, pharmaceutical credibility and regional
infrastructure and marketing expertise for long-term distribution of MED3000
Eroxon™ across the globe.

 

To date, Futura has signed commercial agreements in key markets including;
European Economic Area (EEA), the United Kingdom, the Gulf Co-operation
Council (GCC) region, Switzerland and South Korea, and now has a strong and
expanding distribution platform in place for regions outside the key US
market. As announced in December Futura's corporate advisors formally
commenced the search for a US commercial partner and continue to be engaged in
a number of ongoing discussions.

 

ENDS

 

 

 

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com
(mailto:Investor.relations@futuramedical.com)

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Current therapeutic areas are sexual
health, including erectile dysfunction, and pain relief. Development and
commercialisation strategies are designed to maximise product differentiation
and value creation whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a breakthrough treatment
for erectile dysfunction ("ED") through a unique evaporative mode of action.
Futura has previously conducted a Phase 3 study using MED3000 in ED, referred
to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre,
randomised, double blind, placebo-controlled, home use, parallel group study
delivering highly statistically significant results compared to pre-treatment
baseline, using measures IIEF-EF, SEP2 and SEP3 (internationally accepted
clinical trial endpoints in ED) with over 60% of patients experiencing a
clinically meaningful improvement in their ED.

 

MED3000 is CE marked in Europe and CA marked in the UK as a clinically
proven topical treatment for adult men with erectile dysfunction under the
brand Eroxon™ with a key claim of "Helps you get an erection within 10
minutes".

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com)

 

About Cooper Consumer Health Group (CCH)

Cooper Consumer Health Group (CCH) is the largest independent selfcare
organization in Europe that is active in the OTC consumer healthcare market
with the development, manufacturing, selling and marketing of selfcare
products (e.g., medicines, medical devices, cosmetics, biocides and food
supplements) under its own or licensed brands.

The ambition of our group is to offer selfcare solutions to everyone based on
a European brands portfolio. CCH has proven its capacity to integrate new
activities and aggregate talents by capitalising on the strengths and the
structure of its group. www.cooper-healthcare.com
(http://www.cooper-healthcare.com/)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASEFFMIEDSEFF